Diagnostic Criteria for Enduring Sexual Dysfunction After Treatment With Antidepressants, Finasteride, and Isotretinoin

    David Healy, Audrey S. Bahrick, Maarten Bak, Angelo Barbato, Rocco Salvatore Calabrò, Barbara Chubak, Fiammetta Cosci, Antonei B. Csoka, Barbara D'Avanzo, Silvia Diviccaro, Silvia Giatti, Irwin Goldstein, Heiko Graf, Wayne J.G. Hellstrom, Michael S. Irwig, Emmanuele A. Jannini, Paddy K.C. Janssen, Mohit Khera, Manoj Therayil Kumar, Joanna Le Noury, Michał Lew-Starowicz, David Edmund Johannes Linden, C. Lüning, Dee Mangin, Roberto Cosimo Melcangi, Omar Walid Muquebil Ali Al Shaban Rodríguez, Jalesh N. Panicker, Arianna Patacchini, Amy M. Pearlman, Caroline F. Pukall, Sanjana Raj, Yacov Reisman, Rachel Rubin, Rudy Schreiber, Stuart Shipko, Barbora Vašečková, Ahad Waraich
    TLDR The document sets criteria for diagnosing long-term sexual dysfunctions caused by certain medications.
    The document establishes diagnostic criteria for enduring sexual dysfunctions following the use of antidepressants, finasteride, and isotretinoin, including conditions like post-SSRI sexual dysfunction (PSSD), post-finasteride syndrome (PFS), and post-retinoid sexual dysfunction (PRSD). Common symptoms are decreased genital sensation, reduced sexual desire, and erectile dysfunction. The criteria were developed from two large case series and refined by a multidisciplinary panel to improve diagnosis and research, acknowledging potential future adjustments. The document also introduces Post-SSRI asexuality, linked to early SSRI exposure, and notes that similar dysfunctions may arise from other drugs like antipsychotics and NOACs.
    Discuss this study in the Community →

    Research cited in this study

    7 / 7 results

    Related Community Posts Join

    6 / 1000+ results

    Similar Research

    5 / 1000+ results